Lymphoma Research Foundation Awards 24 Grants to Next Generation of Lymphoma Scientists to Advance Critical Research Foundation Underscores Commitment to Lymphoma Research with Multi-Million Dollar Investment The Lymphoma Research Foundation, the nation’s largest nonprofit organization devoted to funding innovative lymphoma…
Updates from the 2024 American Society of Hematology Annual Meeting The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 264 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific…
ASH 2024: Inequitable Patterns in Fertility Counseling Reported by Patients with NHL Late effects from non-Hodgkin lymphoma (NHL) treatment can lead to decreased fertility, which may be of particular concern for adolescents and young adults. Utilization of fertility counseling is…
ASH 2024: Real-World Clinical Outcomes With Novel Therapies in Relapsed/Refractory MCL Vary Based on Race and Ethnicity The treatment for relapsed/refractory mantle cell lymphoma (MCL) has been revolutionized by the emergence of novel therapies such as Bruton’s tyrosine kinase inhibitors…
ASH 2024: First-Line Treatment Choice Impacts Risk for Other Malignancies in CLL and SLL Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have previously been shown to be at increased risk for developing other malignancies relatively to…
ASH 2024: Interim Results from the AMPLIFY Study Show Durable Responses with Acalabrutinib Plus Venetoclax in Treatment-Naïve CLL Use of fixed-duration Bruton tyrosine kinase inhibitor (BTKi) therapy in treatment-naïve chronic lymphocytic leukemia (CLL) is complicated by the limited efficacy and…
ASH 2024: High Rates of Disease Control Without Radiotherapy Observed Following Incorporation of Nivolumab in Early Stage cHL As treatment options for classic Hodgkin lymphoma (cHL) have improved, minimizing late effects while maximizing treatment efficacy has become a critical goal…
ASH 2024: Phase III Study of Glofitamab Plus Pola-R-CHP Ongoing in Patients with Previously Untreated CD20-Positive LBCL Combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, known as R-CHOP, is a standard first-line treatment option for patients with diffuse large…
ASH 2024: High Response Rates Observed with Loncastuximab Tesirine Plus Rituximab in High-Risk Patients with Relapsed/Refractory FL Loncastuximab tesirine (loncastuximab) is an antibody-drug conjugate used to treat certain types of B-cell lymphomas. The phase I study of loncastuximab showed promise…
